Section Arrow
GRCE.NASDAQ
- Grace Therapeutics Inc
Quotes are at least 15-min delayed:2026/07/05 16:30 EDT
Regular Hours
Last
 2.37
+0.13 (+5.80%)
Day High 
2.39 
Prev. Close
2.24 
1-M High
2.69 
Volume 
268.97K 
Bid
2.3
Ask
2.37
Day Low
2.26 
Open
2.26 
1-M Low
2.0782 
Market Cap 
36.45M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.31 
20-SMA 2.31 
50-SMA 2.39 
52-W High 5.18 
52-W Low 1.79 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.47/-0.88
Enterprise Value
36.45M
Balance Sheet
Book Value Per Share
3.93
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1425+0.0277+24.13%-- 
PPCBPropanc Biopharma Inc.1.77+0.33+22.92%0PE
RXRXRecursion Pharmaceuticals3.8+0.13+3.54%-- 
IOVAIovance Biotherapeutics4.31+0.34+8.56%-- 
SLSSELLAS Life Sciences Group14.98+1.71+12.89%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipinefor the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.